Selective estrogen receptor degrader
Novel tetracyclic SERDs address the limitations of existing SERDs by enhancing ER degradation and transcriptional inhibition, offering effective treatment for ER-positive breast and lung cancers through combination therapies.
Patent Information
- Application Number
- JP2024159222
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-12
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2039-07-11
AI Technical Summary
Existing selective estrogen receptor degraders (SERDs) are not effective enough for treating various cancers, particularly breast, ovarian, endometrial, prostate, uterine, stomach, and lung cancers, due to inadequate pharmacokinetic and pharmacodynamic properties and low oral bioavailability.
Development of novel tetracyclic compounds that act as SERDs, inhibiting ER-mediated transcription and combining with other therapeutic agents like SERMs, aromatase inhibitors, CDK4 inhibitors, CDK6 inhibitors, PI3K inhibitors, and mTOR inhibitors, to enhance treatment efficacy.
The novel SERDs demonstrate potent ER degradation and transcriptional inhibition, showing significant anti-proliferative effects in cancer cells and tumor regression, with good oral bioavailability and efficacy in ER-positive breast and lung cancer models.
Smart Images

Figure 2024169490000001 
Figure 2024169490000002 
Figure 2024169490000003
Abstract
Description
[Background technology]
[0001] Selective estrogen receptor degraders (SERDs) bind to estrogen receptors (ERs) and downregulate ER-mediated transcriptional activity. This degradation and downregulation caused by SERDs may be useful in treating cell proliferation disorders such as cancer. Several small molecule examples of SERDs have been disclosed in the literature (see, for example, WO2005073204, WO2014205136, and WO2016097071). However, the known SERDs are not as useful as needed to effectively treat cancer. For example, finding a SERD with good pharmacokinetic (PK) and pharmacodynamic (PD) properties, high efficiency in the clinic, and good oral bioavailability would be very helpful in treating cancer. Pure antagonist SERDs that potently inhibit ER-mediated transcription would be clearly beneficial in treating cancer. New SERDs are needed to treat cancers such as breast, ovarian, endometrial, prostate, uterine, gastric, and lung cancers, as well as new resistance-driven mutations. In particular, new SERDs are needed to treat ER-positive breast, gastric, and / or lung cancer. Summary of the Invention
[0002] formula: [ka] Provided herein is a compound of the formula: 1 or R 2 are independently Cl, F, -CF 3、 or -CH3, and the other is hydrogen.
[0003] Also provided are methods of using the compounds described herein, pharma- ceutically acceptable salts thereof, and pharmaceutical compositions thereof, for treating breast, ovarian, endometrial, prostate, uterine, gastric, or lung cancer, comprising administering a therapeutically effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, to a patient in need thereof.
[0004] Further provided are compounds as described herein, and pharmaceutically acceptable salts thereof, for use in treatment. Compounds as described herein, and pharmaceutically acceptable salts thereof, can be used to treat breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer.
[0005] Further provided is the use of a compound as described herein, and a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0006] Novel tetracyclic compounds and pharmaceutical salts thereof that act as SERDs are disclosed herein. The newly invented SERDs described herein provide inhibition of ER-mediated transcription, which is useful for treating cancers such as breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, and lung cancer, as well as new resistance mutations. These SERDs can be used as single agents or in combination with other classes of drugs, such as selective estrogen receptor modulators (SERMs), aromatase inhibitors, CDK4 inhibitors, CDK6 inhibitors, PI3K inhibitors, and mTOR inhibitors, to treat hormone receptor-positive cancers such as breast cancer, gastric cancer, and / or lung cancer.
[0007] The novel compounds described herein have formula I: [ka] or a pharma- ceutically acceptable salt thereof, 1 or R 2are independently selected from Cl, F, -CF3, or -CH3, and the other is hydrogen. One of ordinary skill in the art will appreciate that compounds as described by Formula I, or pharma- ceutically acceptable salts thereof, contain chiral centers, the positions of which are indicated by * above. One of ordinary skill in the art will also appreciate that the Cahn-Ingold-Prelog priority (R) or (S) designation of a chiral center varies depending on the substitution pattern around the chiral center. The chiral centers of compounds of Formula I may be in the R-enantiomeric form, as shown by Formula II: [ka] and the S-enantiomeric form represented by formula III: [ka] The present invention provides a method for the preparation of a compound according to the present invention, comprising the steps of: (a) providing a compound according to the present invention, comprising the steps of: (a) providing a compound according to the present invention, comprising the steps of: (i ...
[0008] Specific examples of compounds of formula I (including their IUPAC nomenclature names) are shown below. [ka] 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 8-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 7-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 8-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 7-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-methyl-5H-[1]benzopyrano[4,3-c]quinolin-2-ol; [ka] 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-methyl-5H-[1]benzopyrano[4,3-c]quinolin-2-ol.
[0009] Because of the chiral centers described above, each of these specific examples of the compound of formula I above has R- and S-enantiomeric forms (i.e., R-enantiomeric compounds of formula II and S-enantiomeric compounds of formula III), as shown in Table 1. [Table 1-1] [Table 1-2]
[0010] Also described herein are pharmaceutical compositions comprising the compounds of formula I, formula II, and formula III described herein, or pharma- ceutically acceptable salts thereof, in combination with a pharma- ceutically acceptable excipient, carrier, or diluent. The pharmaceutical compositions described herein can be prepared using pharma- ceutically acceptable additives. As used herein, the term "pharma- ceutically acceptable additives" refers to one or more carriers, diluents, and excipients that are compatible with the other components of the composition or formulation and are not harmful to the patient. The compounds of formula I, formula II, and formula III described herein, or pharma- ceutically acceptable salts thereof, can be formulated as pharmaceutical compositions administered by various routes, such as orally or IV. Bioavailability is often a factor in cancer therapy, and the ability to select methods of administration and pharmaceutical compositions to control or optimize the bioavailability of active ingredients is useful. For example, orally bioavailable SERD compositions would be particularly useful. The compounds of formula I, formula II, and formula III described herein, or pharma- ceutically acceptable salts thereof are believed to have oral bioavailability. Examples of pharmaceutical compositions and processes for their preparation can be found in "Remington: The Science and Practice of Pharmacy", LV Allen Jr, Editor, 22nd Ed., Mack Publishing Co., 2012. Non-limiting examples of pharma- ceutically acceptable carriers, diluents, and excipients include: saline, water, starch, sugars, mannitol, and silica derivatives, carboxymethylcellulose and other cellulose derivatives, alginates, gelatin, and binders such as polyvinylpyrrolidone, kaolin and bentonite, and polyethyl glycols.
[0011] Further described herein is a method of treating cancer. The method described herein comprises administering to a patient in need of such treatment an effective amount of a compound of formula I, formula II, and formula III as described herein, or a pharma- ceutically acceptable salt thereof. For example, the method of administering an effective amount of a compound of formula I, formula II, and formula III as described herein, or a pharma- ceutically acceptable salt thereof can be oral administration. The cancer can be an estrogen-responsive cancer. Furthermore, the cancer can be breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer. For example, the cancer can be ER-positive breast cancer, ER-positive gastric cancer, or ER-positive lung cancer.
[0012] Also described herein are compounds of formula I, II, and III, or their pharmaceutically acceptable salts, for use in treatment.Also provided herein are compounds of formula I, II, and III, or their pharmaceutically acceptable salts, for use in treatment of breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer.In particular, breast cancer can be ER-positive breast cancer, ER-positive gastric cancer, or ER-positive lung cancer.For example, compounds of formula I, II, and III, or their pharmaceutically acceptable salts, can be administered orally.
[0013] Furthermore, the compounds of formula I, formula II, and formula III described herein, or their pharmaceutically acceptable salts, can be used to manufacture medicaments for the treatment of cancer.For example, the medicaments can be administered orally.The types of cancer that the medicaments described herein can be used to treat include breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer.In particular, the cancer can be ER-positive breast cancer, ER-positive gastric cancer, or ER-positive lung cancer.
[0014] The compounds of formula I, formula II, and formula III described herein, and their pharmaceutically acceptable salts, may have clinical utility as single agents or in combination with one or more other therapeutic agents (e.g., anti-cancer agents) for the treatment of cancers such as breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, lung cancer, etc. When used in combination with other therapeutic agents (such as anti-cancer agents), the compounds of formula I, formula II, and formula III described herein, or their pharmaceutically acceptable salts, may be used simultaneously, sequentially, or separately with the other therapeutic agents. Examples of classes of drugs that may be combined with the compounds of formula I, formula II, and formula III described herein, or their pharmaceutically acceptable salts, include SERMs, aromatase inhibitors, CDK4 inhibitors, CDK6 inhibitors, PI3K inhibitors, and mTOR inhibitors for the treatment of hormone receptor-positive breast cancer. More specific examples of drugs with which the compounds of Formula I, Formula II, and Formula III described herein, or pharma- ceutically acceptable salts thereof, can be combined include abemaciclib (CDK4 / 6 inhibitor), everolimus (mTOR inhibitor), alpelisib (PIK3CA inhibitor), and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (PI3K / mTOR inhibitor).
[0015] As used herein, the term "effective amount" refers to the amount or dose of the compound of formula I, formula II, and formula III described herein, or their pharma- ceutically acceptable salts, which, when administered to a patient in a single or multiple doses, provides the desired effect to the patient under diagnosis or treatment.Preferably, the desired effect is inhibition of tumor cell proliferation, tumor cell death, or both.The compound of formula I, formula II, and formula III described herein, or their pharma-ceutically acceptable salts, is generally effective over a wide dosage range.For example, the daily dosage is usually within the range of about 100 mg to about 2000 mg per day.
[0016] As used herein, "treat," "treating," or "treatment" refers to inhibiting, slowing, halting, or reversing the progression or severity of an existing condition or disorder.
[0017] As used herein, the term "patient" refers to a human suffering from a particular disease, disorder, or condition.
[0018] The compounds of formula I, formula II, and formula III described herein, or their pharmaceutically acceptable salts, can be prepared by various procedures known in the art, some of which are shown in the following preparations and examples.The specific synthetic steps of each described route can be combined with various methods or steps from different procedures to prepare the compounds of formula I, formula II, and formula III described herein, or their pharmaceutically acceptable salts.The products can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization.The reagents and starting materials are readily available to those skilled in the art.
[0019] Intermediates and processes useful for the synthesis of the compounds of formula I, formula II, and formula III described herein are intended to be included in this description. Furthermore, certain intermediates described herein may contain one or more protecting groups. Variable protecting groups may be the same or different from one occurrence to another, depending on the specific reaction conditions and the specific transformation carried out. Protection and deprotection conditions are well known to those skilled in the art and are described in the literature (see, for example, "Greene's Protective Groups in Organic Synthesis", Fourth Edition, by Peter GMWuts and Theodora W. Greene, John Wiley and Sons, Inc. 2007).
[0020] Individual isomers, enantiomers, and diastereomers can be separated or resolved by one of skill in the art using methods such as selective crystallization techniques or chiral chromatography at any convenient point in the synthesis of the compounds of Formula I, Formula II, and Formula III described herein (see, for example, J. Jacques, et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and EL Eliel and SH Wilen, "Stereochemistry of Organic Compounds", Wiley-Interscience, 1994). Individual isomers, enantiomers, and diastereomers can be separated or resolved as described above, although the Cahn-Ingold-Prelog priority (R) or (S) assignment of the chiral centers may not yet be determined. When Cahn-Ingold-Prelog (R) or (S) designations are not available, the identifiers "isomer 1" and "isomer 2" are used and combined with the IUPAC names without the Cahn-Ingold-Prelog stereochemical designation. Compounds of Formula I, Formula II, and Formula III identified herein as "isomer 1" or "isomer 2" are isolated as defined in the specific experimental description below. Whether an isomer is "1" or "2" refers to the order in which compounds of Formula I, Formula II, and Formula III elute from a chiral chromatography column under the conditions described, i.e., "isomer 1" is the first to elute from the column under the conditions described above. The same designations apply to subsequent intermediates and compounds of Formula I, Formula II, and Formula III if chiral chromatography is initiated early in the synthesis.
[0021] Abbreviations used herein are defined according to Aldrichimica Acta, Vol. 17, No. 1, 1984. Other abbreviations are defined as follows: "ACN" refers to acetonitrile. "BSA" refers to bovine serum albumin. "cataCXium® A Pd G3" refers to [(di(1-adamantyl)-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate. "DCM" refers to dichloromethane or methylene chloride. "DMA" refers to dimethylacetamide. "DMEA" refers to dimethylethylamine. "DMEM" refers to Dulbecco's modified Eagle's medium. "DMF" refers to N,N-dimethylformamide. "DMSO" refers to dimethylsulfoxide. "DNA" refers to deoxyribonucleic acid. "cDNA" refers to complementary DNA. "DNase" refers to deoxyribonuclease. "DTT" refers to dithiothreitol. "EC 50 " is a predefined positive control compound (absolute EC 50 ) refers to the concentration of an agent that produces a response of 50% of the target activity. "EDTA" refers to ethylenediaminetetraacetic acid. "ee" refers to enantiomeric excess. "ERα" refers to estrogen receptor alpha. "ERβ" refers to estrogen receptor beta. "EtOAc" refers to ethyl acetate. "EtOH" refers to ethanol or ethyl alcohol. "FBS" refers to fetal bovine serum. "HBSS" refers to Hank's balanced salt solution. "HEC" refers to hydroxyethyl cellulose. "HEPES" refers to 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. "HPLC" refers to high performance liquid chromatography. "IC 50 " is the concentration of a drug that produces 50% of the maximum inhibitory response possible for that drug (relative IC 50 ), or the concentration of drug that produces 50% inhibition of target enzyme activity compared to a placebo control (absolute IC 50 "IPA" refers to isopropylamine. "iPrOH" refers to isopropanol or isopropyl alcohol. "IV" refers to intravenous administration. "k i" refers to the inhibition constant; "MEK" refers to methyl ethyl ketone; "MeOH" refers to methyl alcohol or methanol; "MTBE" refers to methyl t-butyl ether; "PBS" refers to phosphate buffered saline; "PO" refers to oral administration; "PRα" refers to progesterone receptor alpha; "QD" refers to once daily administration; "RNA" refers to ribonucleic acid; "RNase" refers to ribonuclease; "RT-PCR" refers to reverse transcription polymerase chain reaction; "RT-qPCR" refers to reverse transcription quantitative polymerase chain reaction; "SFC" refers to supercritical fluid chromatography; "TED" refers to ELISA. 50 " refers to the dose effective to achieve 50% inhibition of targets in a tumor. "THF" refers to tetrahydrofuran. (R) " refers to retention time. "XantPhos Pd G2" refers to chloro[(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2'-amino-1,1'-biphenyl)]palladium(II). "XPhos Pd G2" refers to chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II).
[0022] The following preparations and examples further illustrate this invention.
[0023] Preparations and Examples [ka]
[0024] In step A, a Grignard reaction is accomplished. The Grignard reaction is well known in the art as a reaction for the formation of carbon-carbon bonds. This reaction involves an organometallic reaction in which a Grignard reagent, an aryl magnesium halide, adds to a carbonyl group, such as an acid chloride, of compound 2, resulting in the compound of step A. For example, a 4-chloro substituted quinolone, compound 1, is treated with a Grignard reagent, such as isopropyl magnesium chloride, to form a Grignard intermediate, followed by the addition of an acid chloride, 4-fluorobenzoyl chloride, compound 2, in a solvent such as THF. Once complete, the reaction can be quenched with water to give compound 3.
[0025] In step B, the aryl methyl ether of compound 3 can be demethylated under a variety of conditions that will be recognized by one of skill in the art, such as treatment with boron tribromide. For example, compound 3 is slowly treated with boron tribromide in a solvent such as DCM at a temperature of about 0° C. The mixture is stirred at room temperature and quenched with potassium phosphate dibasic to give compound 4.
[0026] In step C, the azetidine ether 6 can be formed by treating the corresponding p-fluorophenyl ketone 4 and the azetidine alcohol salt 5, or the corresponding free base, with a suitable base, such as sodium hydride, sodium t-butoxide or potassium t-butoxide, in a suitable polar aprotic solvent such as DMF or THF to produce the ether compound 6.
[0027] Compound 6 is then alkylated with an appropriate substituted arylboronic acid, compound 7, in a Suzuki cross-coupling reaction to give compound 8 in step D. One skilled in the art will recognize that there are a variety of conditions that may be useful to facilitate such cross-coupling reactions. Suitable palladium reagents may include XantPhos Pd G2, cataCXium® APd G3, bis(triphenylphosphine)palladium(II) chloride, tris(dibenzylideneacetone)dipalladium(0) with tricyclohexylphosphine, (1,1′-bis(diphenylphosphino)ferrocene)palladium(II) chloride, palladium tetrakistriphenylphosphine, or palladium(II) acetate. Suitable bases may include potassium fluoride, cesium carbonate, sodium carbonate, potassium carbonate, lithium t-butoxide, or potassium phosphate tribasic monohydrate. For example, compound 6 can be reacted with an appropriate boronic acid, compound 7, e.g., 2-fluoro-4-(trifluoromethyl)phenylboronic acid, in a solvent such as 2-methyl-2-butanol containing a base such as potassium carbonate and a catalyst such as XPhos Pd G2, and heated to about 80° C. under microwave conditions to give compound 8.
[0028] One skilled in the art will recognize that Step D, the Suzuki cross-coupling reaction, may be completed prior to Step C, the azetidine ether formation.
[0029] In step E, one skilled in the art will recognize that compound 8 can be cyclized by initial reduction of the ketone. This can be accomplished using a reducing agent such as lithium triethylborohydride in a solvent such as 1,4-dioxane and THF at temperatures from about 0° C. to room temperature to give the corresponding secondary alcohol. This intermediate alcohol can be carried forward crude and deprotonated with a suitable base such as cesium carbonate, sodium hydride, sodium t-butoxide or potassium t-butoxide in a solvent such as THF, DMSO, or DMF. The resulting alkoxide can be cyclized to an aryl fluoride at room temperature, by heating to reflux, or at a temperature of about 60° C. The substituted cyclic ether formed upon displacement of the fluoride can then be obtained to give a compound of formula I.
[0030] Alternatively, ketone 8 can be reduced to the alcohol and chiral purified in step F to give chiral alcohol 9, which can then be cyclized in step G as described above for step E to give compounds of formula I.
[0031] In another alternative reaction, a chiral reagent such as (R)-(+)-α.α-diphenyl-2-pyrrolidinemethanol can be used with trimethyl borate and borane-dimethylsulfide to reduce the ketone directly to the desired chiral alcohol, compound 9, which can then be cyclized in step G as described above for step E to give compounds of formula I.
[0032] At any step, pharma- ceutically acceptable salts of the compounds of formula I, II, and III described herein can be formed by reacting the appropriate free base of the compounds of formula I, II, and III described herein with an appropriate pharma- ceutically acceptable acid in a suitable solvent under standard conditions. Moreover, the formation of such salts can occur simultaneously with the deprotection of nitrogen protecting groups. The possibility of forming pharma- ceutical acceptable salts is well known. For example, see Gould, PL, "Salt selection for basic drugs," International Journal of Pharmaceutics, 33:201-217 (1986); Bastin, RJ, et al. "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities," Organic Process Research and Development, 4:427-435 (2000); and Berge, SM, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66:1-19, (1977). Those skilled in the art will understand that the compounds of formula I, formula II, and formula III described herein can be easily converted into pharmaceutically acceptable salts and separated as pharmaceutically acceptable salts.Examples of useful salts include, but are not limited to, benzenesulfonate and 4-methylbenzenesulfonate.4-methylbenzenesulfonate is also known as tosylate salt.
[0033] Preparation 1 2-[3-(fluoromethyl)azetidin-1-yl]ethan-1-ol [ka] Sodium triacetoxyborohydride (405 g, 1.91 mol) is added portionwise over 15 min under N2 to a stirred 0 °C solution of 3-(fluoromethyl)azetidine hydrochloride (160 g, 1.28 mol) in DCM (2.4 L) and stirred at 0 °C for 10 min. 1,4-Dioxane-2,5-diol (99 g, 0.83 mol) is added in six portions over 1 h at 0 °C and stirred at 0-5 °C for 15 min. The reaction is warmed to room temperature and stirred under N2 for 2 h. The reaction is cooled to 10-15 °C over 20 min, then warmed to 25-30 °C and maintained at this temperature for 2 h. Water (800 mL) is added over 25-30 min at 10-15 °C and warmed to room temperature for 5-10 min before separating the layers. The aqueous layer is washed with DCM (800 mL) and the layers are separated before cooling the combined aqueous layers to 10-15 °C and adjusting the pH to 13-14 using 50% sodium hydroxide solution (approximately 540 mL). The aqueous layer is allowed to warm to room temperature and extracted with DCM (4 x 800 mL), dried over sodium sulfate (80 g), filtered and concentrated to dryness to give the title compound (139 g, 82%) as a thick yellow oil. ES / MS (m / z): 134.1 (M+H).
[0034] Preparation 2 2-[3-(Fluoromethyl)azetidin-1-yl]ethan-1-ol hydrochloride [ka] Dissolve 2-[3-(fluoromethyl)azetidin-1-yl]ethan-1-ol (529 g, 4 mol) in MTBE (2.6 L) and cool to 0° C. Add HCl / EtOH solution (492 mL, 30 wt%) dropwise over 30 min and stir at 0° C. for 30 min. Filter the solid and wash the filter cake with MTBE (2×200 mL). Dry under N2 for 8 h to give the title compound (580 g, 86%) as a white solid. ES / MS (m / z): 134.0 (M+H).
[0035] Preparation 3 (3-Chloro-7-methoxyquinolin-4-yl)-(4-fluorophenyl)methanone [ka] A mixture of 4-bromo-3-chloro-7-methoxyquinoline (70 g, 254 mmol) and THF (1 L) is cooled to -40 °C under N2 to precipitate the material. Isopropylmagnesium chloride (2 M in THF, 254 mL, 509 mmol) is added over 20 min and the mixture is stirred for 1 h. A solution of 4-fluorobenzoyl chloride (66 mL, 559 mmol) in THF (140 mL) is added dropwise and then allowed to warm to room temperature. Quench the reaction with saturated NH4Cl solution (300 mL) and water (200 mL) and separate the layers. Wash the organic layer with saturated NH4Cl solution (300 mL), dry over MgSO4, filter and concentrate to yield an oily residue. Filter the crude brown oil through silica gel eluting with a mixture of MTBE / hexanes (1:1) to give the crude product as a yellow solid (84 g). Treat the solid with 10% methyl acetate / heptane (800 mL) and stir at room temperature overnight. Filter to collect the solid and save. Concentrate the filtrate and purify on silica gel eluting with 10-40% EtOAc / hexanes, then treat the product with 10% methyl acetate / heptane (200 mL) and stir at room temperature for 3 h. Filter the resulting solid, combine with the solid from the previous filtration, and dry under vacuum overnight to give the title compound (31 g, 38%) as a yellow solid. ES / MS (m / z): 316.0 (M+H).
[0036] Preparation 4 (3-Chloro-7-hydroxyquinolin-4-yl)-(4-fluorophenyl)methanone [ka] Add boron tribromide (1M in DCM, 295 mL, 295 mmol) to a mixture of (3-chloro-7-methoxyquinolin-4-yl)-(4-fluorophenyl)methanone (31 g, 98 mmol) in DCM (217 ml) and stir the mixture at room temperature for 3 days. Pour the mixture slowly into a 0° C. solution of potassium phosphate dibasic (2M in water, 700 mL) and water (200 mL). Allow the mixture to warm to room temperature and stir for 1 h. Concentrate the solution in vacuum to remove the organic solvent, filter, collect the filtrate and dry the filtrate under vacuum at 45° C. overnight. Treat the solid with DCM / heptane (1:1, 450 mL) and stir overnight. Collect the solid and dry under vacuum overnight to give the title compound (32 g, quantitative yield) as a light brown solid. ES / MS (m / z): 302.0 (M+H).
[0037] Preparation 5 (3-Chloro-7-hydroxyquinolin-4-yl)-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)methanone [ka] To a stirred solution of (3-chloro-7-hydroxyquinolin-4-yl)-(4-fluorophenyl)methanone (5.00 g, 15.3 mmol) in DMF (75 ml) is added 2-[3-(fluoromethyl)azetidin-1-yl]ethan-1-ol hydrochloride (3.90 g, 23.0 mmol), followed by sodium hydride (60% in mineral oil, 3.02 g, 76.8 mmol). Stir under N2 and warm to 40° C. for 45 min. Quench the solution with water and concentrate. Partition the residue between 20% iPrOH / CHCl3 and saturated aqueous sodium bicarbonate, separate, extract the aqueous layer with 2×20% iPrOH / CHCl3, combine the organic extracts, dry the combined organic layers over magnesium sulfate, filter, and concentrate the filtrate to give the crude product as a dark red oil. The crude material is purified by silica gel column chromatography eluting with a gradient of 5-10% 7N NH3 in MeOH / DCM to give the title compound (5.31 g, 84%) as a yellow solid. ES / MS (m / z): 415.0 (M+H).
[0038] Preparation 6 (4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl){3-[2-fluoro-4-(trifluoromethyl)phenyl]-7-hydroxyquinolin-4-yl}methanone [ka] Mixture of (3-chloro-7-hydroxyquinolin-4-yl)-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)methanone (200 mg, 0.48 mmol), 2-fluoro-4-(trifluoromethyl)phenylboronic acid (158 mg, 0.72 mmol), potassium carbonate (202 mg, 1.45 mmol), 2-methyl-2-butanol (3 ml), and water (1 ml) in a microwave vial is degassed with N2 (5x). XPhos Pd G2 (12 mg, 0.015 mmol) is added, sealed, and microwaved at 80 °C for 2 h. Partition the residue between MTBE and saturated NH4Cl solution. Separate the layers and extract the aqueous layer with MTBE. Combine the organic extracts, dry over magnesium sulfate, filter, and concentrate the filtrate to give an orange residue. The crude material is purified by silica gel column chromatography eluting with 5% MeOH / DCM to give the title compound (205 mg, 78%) as a yellow solid. ES / MS (m / z): 543.2 (M+H).
[0039] The following compounds are prepared in a manner essentially similar to that of Preparation 6, with procedural variations of 1-2 h heating time, extraction with MTBE or EtOAc, and drying of the organic layer over magnesium sulfate or sodium sulfate. Purify by silica gel column chromatography using up to 10% (MeOH or 7M ammoniated MeOH) in DCM (Preparation 10: gradient 3-8% 7M ammoniated MeOH in DCM; Preparations 9 and 11: gradient 4-10% 7M ammoniated MeOH in DCM) and / or by high pH reverse phase chromatography as above. [Table 2-1] [Table 2-2]
[0040] Preparation 14 Racemic 4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)(hydroxy)methyl]-3-[2-fluoro-4-(trifluoromethyl)phenyl]quinolin-7-ol [ka] Add (4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl){3-[2-fluoro-4-(trifluoromethyl)phenyl]-7-hydroxyquinolin-4-yl}methanone (305 g, 562.2 mmol) and THF (1.5 L) together under N2 and cool the solution to 0-5 °C. Add lithium triethylborohydride (1 M in THF, 1.5 L, 1.5 mol) dropwise. Stir the mixture at 0-5 °C for 1 h. Add water (300 mL) dropwise and add saturated NH4Cl (1 L). Cool the mixture to room temperature. Add EtOAc (2 L) and collect the organic layer. Wash the organic layer with brine (500 mL), dry over MgSO4, filter and concentrate to dryness. The residue is dissolved in a 95:5 mixture of acetone and 2M ammonia in MeOH and filtered through silica gel to give the title compound (264 g, 86.2%) as an orange solid. ES / MS (m / z): 545.2 (M+H).
[0041] Preparation 15 4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)(hydroxy)methyl]-3-[2-fluoro-4-(trifluoromethyl)phenyl]quinolin-7-ol, isomer 1 [ka] Purify racemic 4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)(hydroxy)methyl]-3-[2-fluoro-4-(trifluoromethyl)phenyl]quinolin-7-ol (354 g, 0.62 mol) using chiral chromatography under the following conditions: column Chiralpak AD-H, 150 x 50 mm, flow rate 300 g / min, UV 350 nm, mobile phase 35% iPrOH with 0.5% DMEA / CO2, column temperature 40 °C to obtain the title compound (171.4 g, 48%) as the first eluting isomer. (R) = 0.79 min, column: 4.6 × 150 mm Chiralpak AD-H, eluted with a mobile phase of 35% iPrOH with 0.5% DMEA in CO2, flow rate of 0.6 mL / min, chiral analytical SFC with UV detection at 350 nm confirms enantiomeric enrichment of isomer 1 to > 98% ee.
[0042] Alternative Preparation 15 To a solution of (R)-(+)-α.α-diphenyl-2-pyrrolidinemethanol (132 mg, 0.52 mmol) in THF (20 mL) is added trimethyl borate (65 mg, 0.62 mmol). The mixture is stirred at room temperature under N2 for 1 h. Borane-dimethylsulfide (2.0 M in THF, 2.6 mL, 5.2 mmol) is added, followed by (4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl){3-[2-fluoro-4-(trifluoromethyl)phenyl]-7-hydroxyquinolin-4-yl}methanone (1.0 g, 1.73 mmol). The reaction is heated at 45 °C overnight. Additional borane-dimethylsulfide (2.0 M in THF, 2.6 mL, 5.2 mmol) is added and stirred at 45 °C for 5 h. Slowly add saturated NH4Cl solution (25 mL) and isolate the organic phase. Re-extract the aqueous extract with 20% iPrOH / CHCl3. Combine the organic extracts, dry over Na2SO4, filter and evaporate to give the borane complex intermediate (1.2 g). Dissolve one third of the borane complex intermediate (0.4 g, 0.6 mmol) in 1,4-dioxane (4 mL) and ethanolamine (0.3 mL, 5 mmol) and heat the reaction at 70 °C for 3 h. Quench the reaction with saturated NH4Cl solution (25 mL) and isolate the organic phase. Re-extract the aqueous extract with 20% iPrOH / CHCl3 (4 x 25 mL). Combine the organic extracts, dry over Na2SO4, filter and concentrate to dryness to give the title compound as an orange solid (0.33 g, 0.57 mmol, 100% yield). LC / MS(m / z):[M+H] + 545. t (R) = 0.79 min, column: 4.6 × 150 mm Chiralpak AD-H, eluted with a mobile phase of 35% iPrOH with 0.5% DMEA in CO2, flow rate of 0.6 mL / min, chiral analytical SFC with UV detection at 350 nm confirms enantiomeric enrichment of isomer 1 of 96% ee.
[0043] Example 1 Racemic 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol [ka] Cool a solution of (4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl){3-[2-fluoro-4-(trifluoromethyl)phenyl]-7-hydroxyquinolin-4-yl}methanone (5.27 g, 9.71 mmol) in 1,4-dioxane (100 mL) to 5 °C. Add lithium triethylborohydride (1 M in THF, 30.0 mL, 30.0 mmol). Remove the cooling bath and stir at room temperature for 1.5 h. Quench the mixture with water. Add saturated NH4Cl solution and EtOAc. Separate the layers and extract the aqueous layer with EtOAc. Combine the organic extracts, dry over anhydrous MgSO4, filter, and concentrate the filtrate. Dissolve the crude residue in THF (100 mL). Add sodium hydride (60% solution in mineral oil, 1.94 g, 48.5 mmol). The solution is refluxed for 1.5 h. Additional sodium hydride (60% in mineral oil, 1.94 g, 48.5 mmol) is added, then refluxed for an additional 30 min. The solution is cooled to room temperature and quenched with water. EtOAc and saturated NH4Cl solution are added. The layers are separated and the aqueous layer is extracted with EtOAc. The organic extracts are combined, dried over anhydrous MgSO4, filtered, and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with a gradient of 5-7% MeOH in DCM to give the title compound (3.70 g, 72%) as a pale yellow foam. ES / MS (m / z): 525.2 (M+H).
[0044] The following compounds are prepared in a manner essentially similar to that of Example 1, with variations on the procedure below. For reduction, 3-5 equivalents of lithium triethylborohydride are used, with reaction times ranging from 30 min to 1 h, and the organic layer is dried over magnesium sulfate or sodium sulfate. The crude residue is used directly or purified by silica gel column chromatography eluting with a gradient of 0-5-7.5-10% MeOH in DCM prior to cyclization. The cyclization is completed by refluxing in THF for up to 16 h, or in DMF, from 2 h at room temperature in the case of Example 2 to 2 h at 85° C. in the case of Example 8. Extract with DCM or EtOAc and dry the organic layer over magnesium sulfate or sodium sulfate. by silica gel column chromatography using up to 10% (MeOH or 7M ammoniated MeOH) in DCM (Example 2: gradient 0-10% MeOH in DCM; Example 5: gradient 4-10% 7M ammoniated MeOH in DCM; Example 8: gradient 5-7.5% 7M ammoniated MeOH in DCM) or by high pH reverse phase HPLC as previously described. [Table 3-1] [Table 3-2]
[0045] Example 1A 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 1B 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: Column: LUX® Cellulose-1, 5×25 cm; Eluted with a mobile phase of 30% iPrOH (containing 0.5% DMEA) in CO2; Column temperature: 40° C.; Flow rate: 300 g / min; UV detection wavelength: 270 nm. Example 1A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 525.2 (M+H). t (R) = 1.30 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 30% MeOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to greater than 99% ee. The title compound of Example 1B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 525.2 (M+H). t (R) = 2.03 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 30% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 with 98% ee.
[0046] Alternative Preparation Example 1B Crystalline 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 Stir 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, 4-methylbenzenesulfonic acid, isomer 2 (23.8 g, 0.034 mol) in water (250 mL) at 1000 rpm. Add NaOH (76 μL) and stir the solution for 2 h. Add DCM (600 mL). Separate the mixture, dry the DCM extract over magnesium sulfate, filter the material through a syringe filter (0.45 μm) and concentrate to dryness. Allow the material to stand under N2 over the weekend. Add 1:1 EtOH / water (80 mL) and stir the mixture while sonicating. Collect the tan solid by filtration through a nylon membrane to give the title compound (10.47 g, 0.02 mol, 59%).
[0047] X-ray powder diffraction (XRD) XRPD patterns of crystalline solids are obtained on a Bruker D4 Endeavor X-ray powder diffractometer operating at 35 kV and 50 mA, equipped with a CuKα source and Vantec detector. Samples are scanned from 4 to 40 2θ° with a 1.0 mm divergence slit, a 6.6 mm fixed anti-scatter slit, and an 11.3 mm detection slit, at a step size of 0.008 2θ° and a scan rate of 0.5 sec / step. Dry powder is loaded into a quartz sample holder and a glass slide is used to obtain a smooth surface. Diffraction patterns of the crystalline forms are collected at ambient temperature and relative humidity. The crystalline peak positions of MDI-Jade are determined after shifting the entire pattern based on an internal NIST675 standard with peaks at 8.853 and 26.774 2θ°. It is well known in the field of crystallography that for any given crystalline form, the relative intensities of the diffraction peaks may vary due to preferred orientation resulting from factors such as crystal morphology and crystal habit. In the presence of preferred orientation effects, the peak intensities change, but the characteristic peak positions of the polymorphs do not. See, for example, The United States Pharmacopeia #23, National Formulary #18, pages 1843-1844, 1995. Furthermore, it is well known in the field of crystallography that for any given crystalline form, the angular peak positions may vary slightly. For example, peak positions may vary due to variations in the temperature at which the sample is analyzed, sample displacement, or the presence or absence of an internal standard. In the present case, the variation in peak positions of 0.2 2θ° is estimated to take into account these potential variations without preventing unambiguous identification of the indicated crystalline form. Confirmation of the crystalline form may be based on any unique combination of prominent peaks.
[0048] The prepared crystalline 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 sample is characterized by an XRD pattern using Cu Ka radiation with a diffraction peak (2-theta value) of 0.2 degrees, in particular a peak at 19.8 in combination with one or more peaks selected from the group consisting of 6.8, 16.0, and 22.1, as set forth in Table 3 below. [Table 4]
[0049] Alternative Preparation Example 1B 4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)(hydroxy)methyl]-3-[2-fluoro-4-(trifluoromethyl)phenyl]quinolin-7-ol, isomer 1 (63.05 g, 104.7 mmol) is dissolved in DMSO (1.3 L) at room temperature under N2. Cesium carbonate (108 g, 331 mmol) is added portionwise over 5 min. The mixture is heated to 60 °C for 15 h. The mixture is cooled to room temperature and diluted with water (2.1 L) and EtOAc (1.3 L). The mixture is stirred for 5 min and separated. The aqueous material is re-extracted with EtOAc (1.3 L) and stirred for 5 min. The organic extracts are separated and combined, washed with brine, water, and EtOAc. Dry the organic extract over MgSO4, concentrate, and dry under high vacuum at room temperature overnight to give the title compound (52.69 grams, 95.9 percent) as a brown solid. (R) = 2.03 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 30% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms the enantiomeric enrichment of Example 1B of 98.1% ee.
[0050] Example 2A 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 2B 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: Column: CHIRALPAK® IC, 21×250 cm; Eluted with a mobile phase of 30% iPrOH (with 0.2% IPA) in CO2; Column temperature: 40° C.; Flow rate: 70 g / min; UV detection wavelength: 225 nm. Example 2A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 525.1 (M+H). t (R) = 1.56 min, column: CHIRALPAK® IC, 4.6 × 150 mm; elution with a mobile phase of 30% iPrOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 1 to greater than 99% ee. The title compound of Example 2B is isolated to give the second eluting enantiomer (isomer 2). ES / MS (m / z): 525.2 (M+H). t (R) = 2.33 min, column: CHIRALPAK® IC, 4.6 × 150 mm; elution with a mobile phase of 30% iPrOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 with 98% ee.
[0051] Example 3A 8-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 3B 8-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 8-chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: CHIRALCEL® OD-H, 21×250 cm; eluted with a mobile phase of 35% MeOH (with 0.2% IPA) in CO2; column temperature: 40° C.; flow rate: 80 g / min; UV detection wavelength: 225 nm. Example 3A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 491.0 (M+H). t (R) = 1.55 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to be greater than 99% ee. The title compound of Example 3B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 491.0 (M+H). t (R) = 2.26 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 to > 99% ee.
[0052] Example 4A 7-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 4B 7-Chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 7-chloro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: CHIRALCEL® OD-H, 21×250 cm; eluted with a mobile phase of 35% MeOH (with 0.2% IPA) in CO2; column temperature: 40° C.; flow rate: 80 g / min; UV detection wavelength: 225 nm. Example 4A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 491.0 (M+H). t (R) = 1.71 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to be greater than 99% ee. The title compound of Example 4B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 491.0 (M+H). t (R) = 2.38 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 to > 99% ee.
[0053] Example 5A 8-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 5B 8-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 8-fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: CHIRALCEL® OD-H, 21×250 cm; eluted with a mobile phase of 30% MeOH (with 0.2% IPA) in CO2; column temperature: 40° C.; flow rate: 80 g / min; UV detection wavelength: 225 nm. Example 5A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 475.0 (M+H). t (R) = 1.56 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 30% MeOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to greater than 99% ee. The title compound of Example 5B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 475.0 (M+H). t (R) = 2.29 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 30% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 to > 99% ee.
[0054] Example 6A 7-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 6B 7-Fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 7-fluoro-5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: CHIRALCEL® OD-H, 21×250 cm; eluted with a mobile phase of 35% MeOH (with 0.2% IPA) in CO2; column temperature: 40° C.; flow rate: 80 g / min; UV detection wavelength: 225 nm. Example 6A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 475.0 (M+H). t (R) = 1.32 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to be greater than 99% ee. The title compound of Example 6B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 475.0 (M+H). t (R) = 1.95 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 35% MeOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 to > 99% ee.
[0055] Example 8A 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-methyl-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 1 and Example 8B 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-methyl-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 [ka] The two enantiomers of 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-7-methyl-5H-[1]benzopyrano[4,3-c]quinolin-2-ol are separated by chiral SFC under the following conditions: Column: CHIRALCEL® OD-H, 21×250 cm; Eluted with a mobile phase of 30% iPrOH (with 0.2% IPA) in CO2; Column temperature: 40° C.; Flow rate: 80 g / min; UV detection wavelength: 265 nm. Example 8A is obtained as the first eluting enantiomer (isomer 1). ES / MS (m / z): 471.2 (M+H). t (R) = 1.47 min, Column: CHIRALCEL® OD-H, 4.6 × 150 mm; Elution with a mobile phase of 30% iPrOH (0.2% IPA) in CO2, Column temperature: 40 °C; Flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of Isomer 1 to be greater than 99% ee. The title compound of Example 8B is isolated to give the second eluting enantiomer (Isomer 2). ES / MS (m / z): 471.2 (M+H). t (R) = 2.05 min, column: CHIRALCEL® OD-H, 4.6 × 150 mm; elution with a mobile phase of 30% iPrOH (0.2% IPA) in CO2, column temperature: 40 °C; flow rate: 5 mL / min; UV detection wavelength: 225 nm confirms enantiomeric enrichment of isomer 2 to > 99% ee.
[0056] Example 9 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2, benzenesulfonic acid [ka] A slurry of 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 (Example 1B) (100 mg, 0.19 mmol) in ACN (3 mL) is heated at 50° C. A solution of benzenesulfonic acid monohydrate (40 mg, 0.23 mmol) in ACN (1 mL) is added. The clear yellow solution is heated at 50° C. for 10 min. Heat is discontinued, the reaction mixture is cooled to room temperature, and the mixture is stirred overnight. Toluene (2 mL) is added and the reaction mixture is stirred for 2 h. The solution is filtered, the resulting solid is collected, and the solid is washed with ACN (1 mL). The solid is dried under vacuum to give the title compound (74 mg, 55%).
[0057] Alternative Preparation Example 9 A slurry of 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 (Example 1B) (124.1 mg, 0.24 mmol) in MEK (4 mL) is heated at 50° C. A solution of benzenesulfonic acid monohydrate (50 mg, 0.28 mmol) dissolved in MEK (1 mL) is added. Heat is discontinued, the reaction mixture is cooled to room temperature, and the mixture is stirred over the weekend. Concentrate under a stream of N2. Add MEK (1 mL) and the slurry to give a yellow crystalline solid. The solid is collected, washed with MEK, and dried under vacuum at room temperature to give the title compound (78.8 mg, 48%).
[0058] XRD, Example 9 XRD is completed according to the description of Example 1B. The prepared sample of -(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2, benzenesulfonic acid is characterized by an XRD pattern using Cu Ka radiation, as listed in Table 4 below, with diffraction peaks (2 theta values), specifically a peak at 20.5 in combination with one or more peaks selected from the group consisting of 12.3, 22.2, and 23.1, with a diffraction angle tolerance of 0.2 degrees. [Table 5]
[0059] Example 10 Crystalline 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, 4-methylbenzenesulfonic acid, isomer 2 [ka] 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, isomer 2 (Example 1B) (204.2 g, 389 mmol) is added together with EtOAc (5 L) and stirred at 60° C., followed by MeOH (200 mL) at 60° C. to give a clear brown solution. The solution is seeded with the title product (11.48 g), followed by a premixed solution of 4-methylbenzenesulfonic acid, hydrate (81.4 g, 428 mmol) in EtOAc (800 mL) to give a yellow suspension. The suspension is stirred at 50° C. for 30 min. The suspension is concentrated to ½ volume. The solution is cooled at room temperature for 1 h, filtered, the solid is collected, and the solid is washed with EtOAc. The solid was dried under vacuum at 30° C. over the weekend to give the title compound (239 g, 343 mmol). To further purify the material, the title compound (229 g, 328.7 mmol) was added together with 2-propanol (4.6 L) and heated at 60° C. for 2 h. Cool to room temperature for 30 min. Filter the solid and wash with iPrOH (100 mL). Dry the solid overnight under a stream of N2 to give the title compound (174.4 g, 76.2%). Combine different lots of the title compound prepared in essentially the same way and add heptane (2 L). Stir the suspension for 30 min, filter the solid and wash with heptane (300 mL). Dry the solid overnight under a stream of N2 and collect to give the title compound (199.7 g, 99.5%).
[0060] XRD, Example 10 XRD is completed according to the description of Example 1B. The prepared crystalline 5-(4-{2-[3-(fluoromethyl)azetidin-1-yl]ethoxy}phenyl)-8-(trifluoromethyl)-5H-[1]benzopyrano[4,3-c]quinolin-2-ol, 4-methylbenzenesulfonic acid, isomer 2 (Example 10) sample is characterized by an XRD pattern using Cu Ka radiation, as set forth in Table 5 below, with diffraction peaks (2-theta values), in particular a peak at 20.1 in combination with one or more peaks selected from the group consisting of 12.8, 19.5, and 22.8, with a diffraction angle tolerance of 0.2 degrees. [Table 6]
[0061] Biological assays Evidence for a relationship between ER expression and certain cancers is well known in the art.
[0062] The results of the following assays indicate that the compounds of Formula I, Formula II, and Formula III of the Examples are active SERDs and are believed to be useful in the treatment of cancer.
[0063] Competitive binding assay of ERα (wild type), ERα (Y537S mutant), and ERβ The purpose of the following ER competitive binding assay is to determine the affinity of test compounds for ERα (wild type), ERα (Y537S mutant), and ERβ.
[0064] 0.025 μCi per well in a buffer containing 50 mM HEPES, pH 7.5, 1.5 mM EDTA, 150 mM NaCl, 10% glycerol, 1 mg / mL ovalbumin, and 5 mM DTT. 3Perform competitive binding assays using H-estradiol (118 Ci / mmol, 1 mCi / mL), 7.2 ng / well of ERα (wild type), or 7.2 ng / well of ERα (Y537S mutant) or 7.7 ng / well of ERβ receptor. Add test compounds at 10 concentrations ranging from 10,000 nM to 0.5 nM and determine nonspecific binding in the presence of 1 μM 17-β estradiol. After incubating the binding reactions (140 μL) at room temperature for 4 h, add cold dextran-charcoal buffer (70 μL) (containing 0.75 g of charcoal and 0.25 g of dextran per 50 mL of assay buffer) to each reaction. Mix the plate on an orbital shaker at 4 °C for 8 min and centrifuge at 3000 rpm, 4 °C for 10 min. An aliquot (120 μL) of the mixture is transferred to another 96-well white flat-bottom plate (Costar) and Perkin Elmer Optiphase Supermix scintillation fluid (175 μL) is added to each well. The plate is sealed and shaken vigorously on an orbital shaker. After 2.5 h of incubation, the plate is read on a Wallac Microbeta counter. The IC was calculated using a four-parameter logistic curve fit. 50 Calculate the IC of the compound and calculate the % inhibition at 10 μM. 50 The value is calculated using the Cheng-Prusoff equation: i The results of this assay, as shown in Table 7 below, demonstrate that Examples 1, 1A, and 1B (and others) bind to recombinant ERα wild type and ERα mutant (Y537S), with Example 1B also binding to recombinant ERα wild type and ERα mutant (Y537S) with a K i Binds to ERβ with ERβ competition of (nM), n=3. [Table 7]
[0065] Of the exemplary compounds tested, the Ki of ERα wild type ranged from about 0.300 nM to about 65 nM. The Ki of ERα Y537S mutant ranged from about 2 nM to 300 nM. The results of this assay show the binding affinity and potency of the exemplary compounds for ERα wild type, mutant (ESR1 Y537S), and ERβ proteins.
[0066] ERα degradation assay in MCF7 cells The purpose of the following ERα degradation assay is to measure the degradation of ERα by test compounds in an ERα positive breast cancer cell line such as MCF7.
[0067] Culture MCF7 (purchased from ATCC HTB-22) cells in DMEM medium supplemented with 10% FBS, 0.01 mg / mL human insulin 1, and 1% penicillin / streptomycin antibiotics and seed them into 384-well flat-bottom plates at a density of 4,000 cells per well in phenol red-free DMEM medium (20 µL) containing 10% charcoal-stripped FBS. Incubate the cells overnight in a cell culture incubator (5% CO2, 95% relative humidity, 37 °C) to allow the cells to attach to the plate. The next day, dose the cells with test compounds. Prepare test compound serial dilutions (1:3) ranging from 6 µM to 0.0003 µM using an Echo555 acoustic dispenser. Dose the cells by adding 5 µL from the serial dilution plate to the cell plate, resulting in a final DMSO concentration of 0.2% and final test compound concentrations in a dose range of 2 - 0.0001 µM. For the maximum point, use medium containing 0.2% DMSO, and for the minimum point, use fulvestrant diluted to a final concentration of 2 μM in growth medium containing 0.2% DMSO. After administration of the test compound, incubate the cell plate at 37° C. and 5% CO2 for 24 hours. Fix the cells by adding 14% paraformaldehyde (10 μL) for 30 minutes at room temperature. Wash the cells once with PBS (20 μL) and incubate with PBS containing 0.5% (v / v) TWEEN® 20 (20 μL) for 1 hour. Wash the cells with PBS containing 0.05% TWEEN® 20 (2×) and block with 3% BSA (20 μL / well) in PBS containing 0.05% TWEEN® 20 and 0.1% TRITON™ X-100 for 1 hour at room temperature. Primary antibody (20 μL) diluted 1:500 in 1% BSA in PBS containing 0.05% TWEEN® 20 (ERα (clone SP1) monoclonal rabbit antibody #RM-9101-S, Thermo Scientific) is added per well, the plate is sealed and incubated overnight at 4° C. The next day, cells are washed with PBS containing 0.05% TWEEN® 20 (2×) and incubated with secondary antibody (20 μL / well) (1:1000 dilution, goat anti-rabbit IgM ALEXAFLUOR™ 488) in PBS 1% BSA for 105 minutes at room temperature.After washing the plate with PBS (2x20μL), add RNase (Sigma) (20μL of 50μg / mL) and a 1:1000 dilution of propidium iodide in PBS per well (20μL). Seal the plate and incubate for 1 hour at room temperature on the bench (protected from light). Measure ERα by scanning the plate with an ACUMEN EXPLORER™ [a laser-scanning fluorescent microplate cytometer from TTPLABTECH LTD]. Image analysis is based on cellular fluorescent signal to identify positive cells. Identify ER positive cells by the mean intensity. Use the total intensity at 575-640nm from propidium iodide / DNA to identify individual cells. The output of the assay is %ER positive cells. IC is calculated by curve fitting a four parameter logistic for each output using GENE DATA™. 50 The results of this assay demonstrate the potent degradation of ERα induced by the compounds of Formula I, Formula II, and Formula III described herein in MCF7 breast cancer cells. Relative IC of Examples 1, 1A, and 1B 50 The values are shown in Table 8. [Table 8]
[0068] Specifically, the results in Table 7 show potent degradation of ERα by the compound of Example 1 in MCF7 breast cancer cells. Among the exemplary compounds tested, the relative IC 50 ranged from 0.003 to >2 μM, indicating that all but Example 2B showed activity at the concentrations tested. The results of this assay indicate that the compounds of formula (I) are SERDs with potent ERα degrading activity in cells.
[0069] PRα induction assay in MCF7 cells The purpose of the following PRα induction assay is to determine whether a test compound has agonist activity at the ERα receptor (agonists are predicted to activate the receptor).
[0070] Culture MCF7 (purchased from ATCC HTB-22) in DMEM medium supplemented with 10% FBS, 0.01 mg / mL human insulin 1, and 1% penicillin / streptomycin antibiotics, and seed the cells (before they are 70% confluent) into 384-well flat-bottom plates at a density of 4,000 cells per well in a 20 μL volume in DMEM phenol red-free medium containing 10% FBS (charcoal-treated). Incubate the cells overnight in a cell culture incubator (5% CO2, 95% relative humidity, 37 °C) to allow the cells to attach to the plate. The next day, dose the cells with test compounds. Prepare compound serial dilutions (1:3) ranging from 6 μM to 0.0003 μM using an Echo555 acoustic dispenser. Dosing the cells by adding test compound (5 μL) from the serial dilution plate to the cell plate produces a final DMSO concentration of 0.2%, with final concentrations of test compound ranging from 2 to 0.0001 μM in doses. For the maximum point, use medium containing 0.2% DMSO, and for the minimum point, use fulvestrant diluted in growth medium containing 0.2% DMSO to a final concentration of 2 μM. After dosing the test compound, incubate the cell plate at 37 °C and 5% CO2 for 24 hours. Fix the cells by adding 14% paraformaldehyde (10 μL) for 30 minutes at room temperature. Wash the cells once with PBS (20 μL) and incubate for 1 hour with PBS containing 0.5% (v / v) TWEEN® 20 (20 μL). Wash cells twice with 20 μL PBS containing 0.05% TWEEN® 20 and block with 20 μL / well 3% BSA in PBS containing 0.05% TWEEN® 20 and 0.1% TRITON™ X-100 for 1 h at room temperature. Add 20 μL of 1:500 primary antibody (PR monoclonal mouse anti-human antibody, clone PgR 636 Dako, M3569) diluted in 1% BSA / PBS containing 0.05 TWEEN® 20 per well, seal plates and incubate overnight at 4°C.
[0071] The next day, wash the cells with PBS 0.05% TWEEN® 20 (2 × 20 μL) and incubate with secondary antibody (20 μL / well) (1:1000 dilution, goat anti-rabbit IgM ALEXAFLUOR™ 488) in PBS 1% BSA for 105 min at room temperature. After washing with PBS (2 × 20 μL), add RNase (20 μL of 50 μg / mL) (Sigma) and a 1:1000 dilution of propidium iodide in PBS per well. Seal the plate and incubate for 1 h at room temperature on the bench (protected from light). Scan the plate with ACUMEN EXPLORER™ [a laser-scanning fluorescent microplate cytometer from TTPLABTECH LTD] to measure PRα. Image analysis is based on cell fluorescence signal to identify positive cells. Identify PR-positive cells by the average intensity. Use the total intensity at 575-640 nm from propidium iodide / DNA to identify individual cells. The output of the assay is % PR positive cells. IC values were calculated by curve fitting a four parameter logistic to each output using GENE DATA™. 50 The results of this assay show no significant agonist activity of Examples 1, 1A, and 1B in MCF7 breast cancer cells. The relative IC in this assay is determined for the compounds tested. 50 is >2 μM. The results of this assay show no significant agonist activity of the exemplified compounds tested in MCF7 breast cancer cells. These results also show that the exemplified compounds tested are antagonists of ERα in MCF7 breast cancer cells (i.e., they have SERD activity).
[0072] PRα inhibition (ERα functional antagonism) cellular assay in MCF7-ESR1 Y537N 682 CRISPR cells The purpose of the following PRα inhibition (ERα functional antagonism) cellular assay is to determine the antagonist activity of test compounds against the Y537N mutant ERα receptor. Antagonists in this assay are expected to block ERα receptor function. Because PRα is a downstream transcriptional target of ERα, antagonists of ERα are expected to inhibit expression of PRα.
[0073] Culture MCF7-ESR1 Y537N-682 (generated by CRISPR / Cas9 gene editing of the ESR1 gene in MCF7 cells, clone #682) in DMEM medium supplemented with 10% FBS and 1% penicillin / streptomycin antibiotics and seed the cells (before they are 70% confluent) into 384-well flat-bottom plates at a density of 4,000 cells per well in DMEM phenol red-free medium, 10% FBS (20 μL volume) (charcoal-treated). Incubate the cells overnight in a cell culture incubator (5% CO2, 95% relative humidity, 37 °C) to allow the cells to attach to the plate. The next day, dose the cells with test compounds. Prepare compound serial dilutions (1:3) ranging from 6 μM to 0.0003 μM using an Echo555 acoustic dispenser. Cells are dosed by adding 5 μL from the serial dilution plate to the cell plate, resulting in a final DMSO concentration of 0.2% and a final test compound concentration ranging from 2 to 0.0001 μM. For the maximum point, use medium with 0.2% DMSO, and for the minimum point, use fulvestrant diluted in growth medium with 0.2% DMSO to a final concentration of 2 μM. After dosing with the test compound, incubate the cell plate at 37 °C and 5% CO2 for 72 hours. Fix cells by adding 14% paraformaldehyde (10 μL) for 30 minutes at room temperature. Wash cells once with PBS (1 × 20 μL) and incubate with PBS (20 μL) containing 0.5% (v / v) TWEEN® 20 for 1 hour. Wash cells with PBS containing 0.05% TWEEN® 20 (2x20μL) and block with 3% BSA / PBS 0.05% TWEEN® 20, 0.1% TRITON™ X-100 (20μL / well) for 1 hour at room temperature. Add 1:500 primary antibody (20μL) diluted in 1% BSA / PBS 0.05 TWEEN® 20 per well (PR monoclonal mouse anti-human antibody, clone PgR 636 Dako, M3569), seal plates and incubate overnight at 4°C.
[0074] The next day, wash the cells with PBS 0.05% (2 × 20 μL) and incubate with secondary antibody (20 μL / well) (1:1000 dilution, goat anti-rabbit IgM ALEXAFLUOR™ 488) in PBS 1% BSA for 105 min at room temperature. After washing with PBS (2 × 20 μL), add RNase (20 μL of 50 μg / mL) (Sigma) and a 1:1000 dilution of propidium iodide in PBS per well. Seal the plate and incubate for 1 h at room temperature on the bench (protected from light). Scan the plate with ACUMEN EXPLORER™ [laser-scanning fluorescence microplate cytometer from TTPLABTECH LTD] to measure PRα. Image analysis is based on cell fluorescence signal to identify positive cells. Identify PR-positive cells by the average intensity. Use the total intensity at 575-640 nm from propidium iodide / DNA to identify individual cells. The output of the assay is % PR positive cells. IC values were calculated by curve fitting a four parameter logistic to each output using GENE DATA™. 50 Determine.
[0075] The results of this assay demonstrate potent inhibition and functional antagonism of PRα by Examples 1, 1A, and 1B in MCF7 (ESR1 Y537N, heterozygous mutant) breast cancer cells. The relative IC of Examples 1, 1A, and 1B (and others) in this assay 50 are shown below in Table 9. Relative IC 50 range from about 0.0118 to >1.6 μM, indicating that the exemplified compounds are potent antagonists of the ERα mutant (Y537N) and potent inhibitors of ERα-mediated transcription, with the exception of Example 2B at 1.6 μM. PRα (PGR) is also a transcriptional target of ERα, and the results of this assay indicate potent inhibition of ERα-mediated transcription of PRα. [Table 9]
[0076] PRα inhibition (ERα functional antagonism) cellular assay in MCF7 cells The purpose of the following PRα inhibition (ERα functional antagonism) cellular assay is to determine the antagonist activity of test compounds against the ERα receptor. Antagonists in this assay are expected to block the function of the ERα receptor. Because PRα is a downstream transcriptional target of ERα, antagonists of ERα are expected to inhibit expression of PRα.
[0077] The assay conditions are performed as detailed in the ERα Degradation Cell-Based Acumen Assay described above using the MCF7 cell line, except that before dispensing test compounds, the medium is removed from the cell plate and all wells except the negative control wells (column 24 of the plate) are pretreated with assay medium containing 0.47 nM estradiol for 30 minutes. In this assay, immunostaining to detect PRα is performed and PRα is measured by scanning the plate with an ACUMEN EXPLORER™ [a laser-scanning fluorescent microplate cytometer manufactured by TTP LABTECH LTD]. Image analysis is based on cell fluorescence signals to identify positive cells. PRα positive cells are identified by the mean intensity. Total intensity from propidium iodide / DNA at 575-640 is used to identify individual cells. The output of the assay is % PRα positive cells. IC was calculated by curve fitting a four parameter logistic for each output using GENE DATA™. 50 The results of this assay demonstrate the potent inhibition and functional antagonism of PRα by Examples 1, 1A, and 1B in MCF7 breast cancer cells. The relative IC of Examples 1, 1A, and 1B in this assay 50 are shown below in Table 10. Relative IC for exemplary compounds 50range from about 0.029 to >2 μM, indicating that all exemplary compounds tested, except for 1A and 2B, are potent antagonists of ERα wild-type protein and potent inhibitors of ERα-mediated transcription. PRα (PGR) is also a transcriptional target of ERα, and the results of this assay show potent inhibition of ERα-mediated transcription of PRα at the concentrations tested. [Table 10]
[0078] Cell proliferation assay of MCF7 and MCF7-ESR1 Y537N-682 The purpose of the cell proliferation assays below is generally to detect whether a test compound affects cell proliferation.
[0079] Seed MCF7 (purchased from ATCC HTB-22) cells in DMEM phenol red-free medium 10% FBS (20 μL volume) (charcoal-treated) at a density of 2,000 cells per well in clear-bottom 384-well cell culture plates. Seed MCF7-ESRY537N-682 (generated by CRISPR / Cas9 gene editing of the ESr1 gene in MCF7 cells, clone #682) in DMEM medium supplemented with 10% FBS and 1% penicillin / streptomycin antibiotics at a density of 1,000 cells per well. Incubate the plate at 37 °C and 5% CO2. The next day, dose the cells with test compounds. Prepare test compound serial dilutions (1:3) ranging from 60 μM to 0.003 μM using an Echo555 acoustic dispenser. Dose cells by adding 5 μL from the serial dilution plate to the cell plate, resulting in a final DMSO concentration of 0.2% and final test compound concentrations ranging from 20 to 0.001 μM in doses. For the maximum point, use medium with 0.2% DMSO, and for the minimum point, use fulvestrant diluted in growth medium with 0.2% DMSO to a final concentration of 2 μM. After dosing with test compounds, incubate cell plates at 37 °C and 5% CO2. Seven days after addition of test compounds, remove plates from the incubator and add cold EtOH 96% (65 μL) to each well. After 30 min, remove medium and add RNase (20 μL of 50 μg / mL) (Sigma) and a 1:1000 dilution of propidium iodide in PBS per well. Seal plates and incubate for 1 h at room temperature on the bench (protected from light). The plate is scanned with ACUMEN EXPLORER™ [a laser-scanning fluorescent microplate cytometer manufactured by TTPLABTECH LTD]. MCF-7 cell line grows and forms aggregates, and cell number as a number of objects may not be used as readout, therefore cell number can be evaluated by estimated cell number (calculated by area parameter (ratio of total area of total cell population (specified range of peak intensity of FL-1(PI) and average area of single cell population (defined by perimeter))).IC by curve fitting a four parameter logistic for each output using GENE DATA™. 50 Determine the relative IC of Examples 1, 1A, and 1B (and others) in MCF7 ESR1 wild-type and MCF7-ESR1 Y537N mutant cells. 50 are shown below in Table 10. The results of this assay demonstrate potent antiproliferative activity and cell growth inhibition by Examples 1, 1A, and 1B (and others) in MCF7 (ESR1 wild type) and MCF7 (ESR1 Y537N mutant) breast cancer cells. Relative IC 50 ranged from about 0.0035 to 1.176 μM in MCF7 ESR1 wild type and 0.014 to 1.86 μM in MCF7 (ESR1 Y537N mutant) breast cancer cells, indicating that all exemplary compounds tested demonstrate potent anti-proliferative activity and cell growth inhibition in MCF7 (ESR1 wild type) and MCF7 (ESR1 Y537N mutant) breast cancer cells. [Table 11-1] [Table 11-2]
[0080] In vivo target inhibition (IVTI) assay (PGR RT-qPCR assay) in MCF7 tumors The purpose of this IVTI assay is to measure the ability of a test compound (SERD) to inhibit PRα gene expression (transcription) downstream of ERα in xenograft tumors implanted in mice.
[0081] Female NOD SCID mice (22–25 g) from Envigo RMS, Inc., Madison, Wisconsin were injected with 5 × 10 6MCF7 ER positive breast cancer cells (ATCC, #HTB-22) are implanted subcutaneously in 1:1 HBSS+MATRIGEL™ solution (200 μL) in the right flank area. One day prior to tumor cell implantation, 17-β estradiol pellets (0.18 mg / pellet, 90 day release from Innovative research) are implanted subcutaneously. Tumor growth and body weight are measured twice a week starting 7 days after implantation. Tumors with sizes between 150 and 300 mm 3 When the animals reach 100 mg / kg, they are randomized and divided into groups of 5 animals. Animals are orally dosed with either multiple doses of test compound in a test compound specific vehicle (1% hydroxyethylcellulose / 0.25% TWEEN® 80 / 0.05% antifoam in purified water) or vehicle alone for 3 days, and tumors and blood are harvested at desired time intervals after the last dose. Animals are sacrificed using isoflurane anesthesia and cervical dislocation. Tumors are snap frozen and stored at -80°C until processed for RNA isolation and RT-qPCR assays. Blood is collected in EDTA tubes, spun down for plasma, and frozen at -80°C in 96-well plates. Mass spectrometry is used to determine test compound exposure.
[0082] Tumors are disrupted with liquid nitrogen using Matrix D beads (MP Biomedical, #6913-500) in a FASTPREP-24™ Cell Disrupter machine (MP Biomedical) and lysed in 1× RNA lysis buffer (from the RNA isolation kit). After spinning at 14000 rpm for 20 min at 4° C., tumor lysates are transferred to new tubes. RNA is isolated from tumor lysates using the PURELINK® RNA Mini Kit (Invitrogen #12183018A) or RNeasy Mini Kit (Qiagen #74104 and #74106). DNA contamination is removed using the PURELINK® DNase Set (Invitrogen #12185010) or RNase-free DNase Set (Qiagen #79254). Isolated RNA concentration is measured by diluting samples in RNase-free water and measuring absorbance at 260 nm on a plate reader (SpectraMax190). Subtract the average 260 nm absorbance reading of the blank (RNase-free water only) from the 260 nm readings of all other RNA samples. Dilute the RNA samples to equal concentrations in RNase-free water. Synthesize cDNA from the diluted RNA using the First-Strand Synthesis System for RT-PCR (Invitrogen, #18080-051). To perform RT-qPCR, first dilute the cDNA in RNase-free water. Combine 2x Absolute Blue qPCR ROX Mix (Thermo, #AB-4139 / A), PGR primers (Thermo, Hs01556702_m1), and diluted cDNA for each reaction in a PCR plate (Applied Biosystems, #4309849). Amplify the cDNA by incubating the samples at 50 °C for 2 min, followed by 95 °C for 15 min in a thermocycler (ABI Prism 7900HT Sequence Detection System). Continue incubation at 95° C. for 15 seconds followed by 50° C. for 60 seconds for a total of 40 cycles. Cycles are normalized to housekeeping genes and used to calculate % PGR inhibition compared to vehicle alone. Each sample is analyzed in duplicate and the average number is used in the calculation.Percent target (PGR) inhibition is calculated using Excel and XL Fit.
[0083] The results of this assay demonstrate that Example 1B inhibits PRα (PGR) expression in tumor xenograft models. Example 1B inhibits PRα (PGR) expression by about 78% in tumor xenograft models at a dose of 30 mg / kg for 24 hours when administered orally. These results show significant and sustained inhibition of ERα antagonistic activity and ERα-mediated transcriptional activity in vivo in tumor xenograft models.
[0084] In vivo tumor growth inhibition study in ER-positive (ESR1 wild-type) breast cancer xenograft tumor model implanted in mice The objective of the following xenograft tumor inhibition assay is to measure the reduction in transplanted tumor volume in response to test compound administration.
[0085] Human breast cancer cells MCF7 (ATCC#HTB-22) and HCC1428 (ATCC#CRL-2327) were grown in culture and harvested at 5 × 10e 6 Cells are injected subcutaneously into the right rear flank of female NOD SCID mice (22-25 g, Envigo RMS, Inc.) in a 1:1 HBSS+MATRIGEL™ solution (200 μL). 24 hours prior to cell implantation, estrogen pellets (0.18 mg / pellet, 17β-estradiol, 90-day release, Innovative Research) are implanted subcutaneously. Human breast cancer cells T47D (ATCC#HTB-22) are grown in culture and harvested to give 5×10e 6 Cells are injected subcutaneously into the right rear flank of female NOD SCID mice (22-25 g, Envigo RMS, Inc.) in a 1:1 HBSS+MATRIGEL™ solution (200 μL). 24 hours prior to cell implantation, estrogen pellets (0.38 mg / pellet, 17β-estradiol, 90-day release, Innovative Research) are implanted subcutaneously. Human breast cancer cells ZR-75-1 (ATCC#CRL-1500) are grown in culture and harvested to give 5×10e 6Cells are injected subcutaneously in a 1:1 HBSS+MATRIGEL™ solution (200 μL) into the right hind flank of female NOD SCID mice (22-25 g, Envigo RMS, Inc). 24 hours prior to cell implantation, animals receive an intramuscular injection of 50 μl of estradiol valerate (Delestrogen®) (10 mg / mL) and then once every 14 days for the duration of the study. Tumor growth and body weight are measured twice weekly starting 7 days after implantation. Tumors are measured until tumor size reaches 250-350 mm. 3 When the tumor reaches 100 mg / kg, the animals are randomized and divided into groups of 5 animals. The test compound, Example 1B, is prepared in the appropriate vehicle (1% hydroxyethylcellulose / 0.25% TWEEN® 80 / 0.05% antifoam in purified water) and administered by oral gavage once daily (QD) for 28 days. Tumor response is determined by tumor volume measurements taken twice weekly during the course of treatment. Whenever tumor volume is measured, body weight is taken as a general measure of toxicity.
[0086] The compound of Example 1B was found to have delta T / C% values as provided below in Table 12. These results indicate that the compound of Example 1B exhibits good oral bioavailability in mice and demonstrates significant anti-tumor activity or tumor regression in an ER-positive (ESR1 wild-type) human breast cancer xenograft model. [Table 12]
[0087] % regression is calculated when the endpoint volume falls below baseline using the formula: 100*(T-T0) / T0, where T0 is the mean baseline tumor volume for the treatment group.
[0088] The % change in T / C is computed using the grand mean of all groups from baseline (randomization) on Day 32.
[0089] In vivo tumor growth inhibition study in ESR1 mutant (Y537S) breast cancer PDX tumor model (ST941 / HI) implanted in mice The goal of the following xenograft tumor inhibition assay is to measure the reduction in transplanted tumor volume in response to test compound administration in ESR1 mutant and hormone-independent (HI) breast cancer patient-derived xenograft (PDX) models.
[0090] The ST941 / HI PDX model was derived and performed at South Texas Accelerated Research Therapeutics (San Antonio, TX). Tumor fragments were harvested from host animals and implanted into immunodeficient mice (The Jackson Laboratory) and the study was performed with tumor fragments of approximately 125–250 mm 3 The study began with a mean tumor volume of 100 mg / kg / day. The test compound, Example 1B, is prepared in the appropriate vehicle (1% hydroxyethylcellulose / 0.25% TWEEN® 80 / 0.05% antifoam in purified water) and administered by oral gavage for 28 days. Tumor response is determined by tumor volume measurements taken twice weekly during the course of treatment. Whenever tumor volumes are measured, body weights are taken as a general measure of toxicity.
[0091] The compound of Example 1B was found to have delta T / C% values as provided below in Table 13. These results show that the compound of Example 1B exhibits good oral bioavailability in mice and demonstrates significant antitumor activity or tumor regression in ESR1 mutant (Y537S) human breast cancer PDX models. [Table 13]
[0092] % regression is calculated when the endpoint volume falls below baseline using the formula: 100*(T-T0) / T0, where T0 is the mean baseline tumor volume for the treatment group.
[0093] The % change in T / C is computed using the grand mean of all groups from baseline (randomization) on Day 32.
[0094] Combination studies Due to tumor heterogeneity and acquired resistance to endocrine therapy, combination therapy has become essential for ER-positive and advanced / metastatic breast cancer treatment for effective treatment or to overcome acquired resistance.The combination effect of Example 1B with CDK4 / 6 inhibitor abemaciclib, mTOR inhibitor everolimus, PIK3CA inhibitor alpelisib, and PI3K / mTOR inhibitor 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one ("Compound A") was tested in five ER-positive breast cancer cell lines in vitro.
[0095] Cell viability assays for combination studies Seed cells in clear bottom 384-well cell culture plates at the density indicated in Table 14 below in a 20 µL volume of medium as indicated in the table. [Table 14]
[0096] Plates are incubated at 37° C. and 5% CO2. The next day, cells are dosed with the test compound, Example 1B.
[0097] Compounds are prepared as 10 mM DMSO stock solutions and used in dose-response studies starting at the highest concentration of 10 or 1 μM. When two compounds are tested together in a fixed ratio, prepare 1:3 serial dilutions. IC 50Compounds alone for determination start at a concentration of 20 μM. Cells are dosed by adding 5 μL from the serial dilution plate to the cell plate resulting in a final DMSO concentration of 0.2% and final test compound concentrations range from 20 to 0.001 μM doses for single treatments and lower ranges for combinations. For the maximum point, use medium with 0.2% DMSO and for the minimum point, use staurosporine diluted to a final concentration of 2 μM in growth medium with 0.2% DMSO. After dosing with test compounds, incubate the cell plate at 37 °C and 5% CO2. After 2 doubling times of incubation with compounds, remove the plate from the incubator and add cold ethanol 96% (65 μL) to each well. After 30 min, remove the medium and add RNase (20 μL of 50 μg / mL) (Sigma) and a 1:1000 dilution of propidium iodide in PBS per well. Seal the plate and incubate for 1 hour at room temperature (protect from light). Scan the plate with ACUMEN EXPLORER™ [a laser-scanning fluorescent microplate cytometer from TTPLABTECH LTD]. Some cell lines grow and form aggregates, and cell count as a number of subjects may not be used as a readout. Therefore, use the total area population (specified range of peak intensity of FL-1 (PI)) or total intensity of PI to assess cell number.
[0098] In vitro combination data suggest synergy (defined below) in combination with Example 1B and abemaciclib or everolimus in five of five ER-positive breast cancer cell lines, as shown in Table 15. The combination of Example 1B and Compound A is synergistic in four of four ER-positive breast cancer cell lines tested. The combination effect of Example 1B and alpelisib is additive in two of four ER-positive breast cancer cell lines and synergistic in two of four ER-positive breast cancer cell lines. [Table 15]
[0099] Data analysis and interpretation of combined effects The in vitro combination effects are calculated using methods published in the literature (L. Zhao, et al, Front Biosci, 2010, 2:241-249 and L. Zhao, et al, Clin Cancer Res, 2004, 10(23):7994-8004). To identify synergistic or antagonistic interactions between two drugs, curve shift analysis was performed using a customized XL template with the XLFit5 add-in. Single drug curves are fitted using a four-parameter logistic regression. The criteria and constraints used for fitting are: (i) bottom < (-20) is fixed to 0 and (ii) top > 120 is fixed to 100. If all observations are below the user-set threshold, a constant fit is performed with hill = 0 and the IC 50 is considered to be higher than the highest concentration included. The absolute IC 50 Once the IC is obtained, the equivalent concentrations at 50% of activity are calculated for the single agents and combinations. These equivalent concentrations are used together with the measured activities to determine the absolute IC 50 The curves for single agents reach 50% activity at a value of equivalent concentration equal to 1, whereas synergistic combinations reach 50% at lower values and show a shift to the left, and antagonistic combinations show a shift to the right. Equivalent concentration is also related to the CI 50 is the absolute IC of the combination curve 50に Equal to, CI 50 It is used to calculate the combination index (CI) at 50% of activity. 50 Along with the CInn other CIs (combination indexes) at various percentages of activity can be calculated (CI10, CI20, CI30, CI40, CI60, CI70, CI80, CI90). To calculate CInn the equivalent concentrations at various percentages of activity are calculated. For each percentage of activity a margin of error is calculated which is a 95% confidence interval and this confidence interval is used to calculate an upper limit as the addition of the margin of error to the CI and a lower limit as the subtraction of the margin of error to the CI. Upper limit = CI + confidence interval 95% and lower limit = CI - confidence interval 95%. These limits are used to interpret the results.
[0100] The statistical interpretation of each activity percentage is as follows: [Table 16] The biological interpretation of each percentage activity is as follows: [Table 17]
[0101] In vivo combination studies Due to tumor heterogeneity and acquired resistance to endocrine therapy, combination therapy has become essential in ER-positive and advanced / metastatic breast cancer treatment for effective treatment or to overcome acquired resistance. It is hypothesized that combinations of targeted therapies may be more effective in slowing or stopping ER-positive breast cancer. Although a combination of CDK4 / 6 inhibitors and fulvestrant has been approved for the treatment of ER-positive metastatic breast cancer, a high percentage of patients develop resistance due to acquired mutations in ESR1 or PIK3CA. As a potent degrader and antagonist of ERα, oral SERDs such as Example 1B may be more effective in slowing or stopping ESR1 mutant or PIK3CA mutant breast cancer as a single agent or in combination with CDK4 / 6 inhibitors such as abemaciclib, or PI3K / mTOR inhibitors such as Compound A. In that context, the compound of Example 1B is tested for tumor growth inhibition in combination with abemaciclib (see patent) or Compound A (see patent). More specifically, the compound of Example 1B is tested in combination with abemaciclib or Compound A in ESR1 wild-type and PIK3Ca mutant MCF7 breast cancer xenograft models.
[0102] Human breast cancer cells MCF7 (ATCC#HTB-22) were grown in culture and harvested at 5 × 10e 6 Cells are injected subcutaneously in a 1:1 HBSS+MATRIGEL™ solution (200 μL) into the right hind flank of female NOD SCID mice (22-25 g, Envigo RMS, Inc.). 24 hours prior to cell implantation, estrogen pellets (0.18 mg / pellet, 17β-estradiol, 90-day release, Innovative Research) are implanted subcutaneously. Tumor growth and body weight are measured twice weekly starting 7 days after implantation. Tumors with a size of 250-350 mm were cultured at 100 x 100 cm. 3 When the tumor reaches 100 mg / kg, the animals are randomized and divided into groups of 5 animals. The test compound, Example 1B, is prepared in the appropriate vehicle (1% hydroxyethylcellulose / 0.25% TWEEN® 80 / 0.05% antifoam in purified water) and administered by oral gavage for 42 days. The CDK4 / 6 inhibitor (Abemaciclib) is formulated in 1% HEC in 25 mM sodium phosphate buffer, pH 2.0. The PI3K / mTOR inhibitor (Compound A) is formulated in 1% hydroxyethylcellulose / 0.25% TWEEN® 80 / 0.05% antifoam in purified water. Tumor response is determined by tumor volume measurements, which are performed twice a week during the course of treatment. Whenever tumor volume is measured, body weight is taken as a general measure of toxicity. Tumor volume is estimated using the formula: v=lxw2x0.535, where l=larger measured diameter, w=smaller perpendicular diameter.
[0103] statistical analysis Statistical analysis of tumor volume data begins with transforming the data to a logarithmic scale to equalize variance across time and treatment groups. Log volume data are analyzed using a two-way analysis of variance with replicates by time and treatment using the MIXED procedure in SAS software (version 9.3). The correlation model for repeated measures is Spatial Power. Treatment groups are compared to the control group at each time point. Adjusted means and standard errors at each time point are calculated using the MIXED procedure separately for each treatment group. Both analyses account for autocorrelation within each animal and for missing data that occurred when animals with large tumors were removed from the study early. Adjusted means and standard errors (se) are plotted against time for each treatment group. Analysis for tumor volume was performed using log 10 and based on spatial power covariance structures. P values are based on comparisons between two specific groups.
[0104] Combined Analysis Method (Bliss Independence for IVEF Studies) First, a normal repeated measures model is fit to the log volume for group versus time. A contrast statement is then used to test for interaction effects at each time point using the two specific treatments combined. This is equivalent to the Bliss Independence method, which assumes that in theory the tumor volume can reach zero, i.e., completely regress. The expected additive response (EAR) for the combination is calculated based on the tumor volume scale as EAR volume = V1*V2 / V0, where V0, V1, and V2 are the estimated mean tumor volumes for vehicle control, treatment 1 alone, and treatment 2 alone, respectively. If the interaction test is significant, the combination effect is declared statistically above additive depending on the observed mean volume of the combination being smaller than the EAR volume, or below additive depending on it being larger. Otherwise, the statistical conclusion is additive. Furthermore, the range of biologically relevant additive can be defined as X% above and below the EAR volume. Typically, X would be 25-40%. A biological conclusion can then be made as combination above add, add, or below add if the mean volume of the observed combination is below, in the middle, or above the add interval.
[0105] There may be situations where a plateau is the most expected response. In these situations, the Bliss method can be applied directly to the % delta T / C values to obtain the EAR% response: EAR% delta T / C=Y1*Y2 / 100, where Y1 and Y2 are the % delta T / C values for the single agent treatments. Currently, there are no statistical tests to compare the observed % delta T / C in the combination group with the EAR, but the biological criteria above can be applied.
[0106] As shown in Tables 15 and 16, treatment with Example 1B or abemaciclib alone as a single agent resulted in tumor regression of 32% (%dT / C=-32) and 52% (%dT / C=-52), respectively, both statistically significant (p<0.001) compared to vehicle control. The combined effect of Example 1B and abemaciclib was "less than additive", but the combined effect of Example 1B and abemaciclib was significantly better than Example 1B alone (p<0.001). However, the efficacy of single agent abemaciclib was not statistically significant from the combination (P=0.055). The combination is tolerated in animals without significant weight loss. [Table 18] [Table 19]
[0107] As shown in Tables 17 and 18, treatment with Example 1B or Compound A alone as a single agent resulted in tumor regression of 32% (%dT / C=-32) and 36% (%dT / C=-36), respectively, both of which are statistically significant (p<0.001) compared to vehicle control. The combined effect of Example 1B and Compound A was "less than additive", but the combined effect of Example 1B and Compound A was significantly better than Example 1B alone (p<0.001) or Compound A alone (p=0.002*). The combination is tolerated in animals without significant weight loss. [Table 20] [Table 21]
[0108] As shown in Tables 19 and 20, treatment with Example 10 or abemaciclib alone as a single agent resulted in tumor regression of 51% (%dT / C=-51) and 70% (%dT / C=-70), respectively, both of which are statistically significant (p<0.001) compared to vehicle control. The combined effect of Example 10 and abemaciclib was "less than additive", but the combined effect of Example 10 and abemaciclib was significantly better than Example 10 alone (p=0.039). However, the combined effect of Example 10 and abemaciclib was not significantly different from abemaciclib alone (p=0.905). The combination is tolerated in animals without significant weight loss. [Table 22] [Table 23]
[0109] As shown in Tables 21 and 22, treatment with Example 10 or alpelisib alone as single agents resulted in tumor regression of 51% (%dT / C=-51) and 21% (%dT / C=-21), respectively, both statistically significant (p<0.001 and p=0.013) compared to vehicle control. The combined effect of Example 10 and alpelisib was "additive", and the combined effect of Example 10 and alpelisib was significantly superior to Example 10 alone (p=0.009). The combined effect of Example 10 and alpelisib was also significantly superior to alpelisib alone (p=<0.001). The combination is tolerated in animals without significant weight loss. [Table 24] [Table 25]
[0110] As shown in Tables 23 and 24, treatment with Example 10 or everolimus alone as a single agent resulted in tumor regression of 51% (%dT / C=-51) and 50% (%dT / C=-50), respectively, both statistically significant (p<0.001 and p<0.001) compared to vehicle control. The combined effect of Example 10 and everolimus was "additive", and the combined effect of Example 10 and everolimus was significantly better than Example 10 alone (p=0.004). The combined effect of Example 10 and alpelisib was also significantly better than everolimus alone (p=0.04). The combination is tolerated in animals without significant weight loss. [Table 26] [Table 27]
[0111] Oral bioavailability in rats The purpose of the following assay is to demonstrate whether a test compound is orally bioavailable.
[0112] Test compounds are administered to Sprague-Dawley rats at 1 mg / kg IV (using either a vehicle of 20% CAPTISOL®, pH 2 vol. in 25 mM sodium phosphate buffer, or 25% DMA, 15% EtOH, 10% propylene glycol, 25% 2-pyrrolidone, and 25% purified water) or 3 mg / kg PO (using a vehicle of 1% hydroxyethylcellulose, 0.25% polysorbate 80, 0.05% antifoam 1510-US, and vol. purified water). Serial blood samples are taken at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 12 hours after IV bolus administration, and 0.25, 0.5, 1, 2, 4, 8, and 12 hours after oral administration. After treatment with EDTA coagulant, plasma is obtained by centrifugation and stored at -70°C until analysis by LC-MS / MS. Concentrations of test substances are determined in plasma and uploaded to the Watson LIMS™ system, which uses non-compartmental analysis to calculate the area under the curve (AUC) for both IV and PO groups. The oral bioavailability (F%) is calculated using the following formula:
number
[0113] The compound of Example 1B exhibits an F% value of about 50% in the above-mentioned assay, which demonstrates that Example 1B has good oral bioavailability.
Claims
1. A compound of the formula [Formula 1] (In the formula, R 1 Or R 2 are independently Cl, F, or -CF 3 , or -CH 3 and the other is hydrogen; or a pharma- ceutically acceptable salt thereof.
2. The compound is [chemical 2] 2. The compound of claim 1, wherein:
3. The compound is [C3] 2. The compound of claim 1, wherein:
4. The compound is [C4] 3. The compound of claim 2, wherein:
5. 5. The compound of claim 4, wherein the pharma- ceutically acceptable salt is a benzenesulfonate salt.
6. The compound of claim 4, wherein the pharma- ceutically acceptable salt is 4-methylbenzenesulfonate.
7. The compound is [C5] 5. The compound of claim 4,
8. The compound is [C6] 4. The compound of claim 3, wherein:
9. 9. The compound of claim 8, wherein the pharma- ceutically acceptable salt is a benzenesulfonate salt.
10. The compound of claim 8, wherein the pharma- ceutically acceptable salt is 4-methylbenzenesulfonate.
11. The compound is [C7] 9. The compound of claim 8, wherein
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, in combination with a pharma- ceutically acceptable excipient, carrier, or diluent.
13. 13. The pharmaceutical composition of claim 12, comprising one or more other therapeutic agents.
14. A method of treating breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer, comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 12 to 13.
15. 15. The method of claim 14, wherein the breast cancer is ER positive breast cancer.
16. The method of claim 14, wherein the gastric cancer is ER-positive gastric cancer.
17. 15. The method of claim 14, wherein the lung cancer is ER-positive lung cancer.
18. A compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 1 to 13 for use in therapy.
19. 12. A compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for use in the treatment of breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer.
20. 20. A compound or salt thereof for use according to claim 19 in the treatment of ER positive breast cancer.
21. 20. The compound or salt thereof for use according to claim 19 in the treatment of ER positive gastric cancer.
22. 20. The compound or salt thereof according to claim 19 for use in the treatment of ER positive lung cancer.
Citation Information
Patent Citations
Selective estrogen receptor modulators for the treatment of vasomotor symptoms
JP2007519721A
Azetidine estrogen receptor modulator and use thereof
JP2016522262A
Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP2017538725A
Estrogen receptor modulator and use thereof
JP2018504384A
Selective estrogen receptor degrader
JP7557564B2
